Please Wait.....
Report
Hormonal Contraceptives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-02-09 I 111 Pages I Mordor Intelligence
Hormonal Contraceptives Market Analysis
The hormonal contraceptive market is expected to grow from USD 17.31 billion in 2025 to USD 18.06 billion in 2026 and is forecast to reach USD 22.35 billion by 2031 at 4.35% CAGR over 2026-2031. Expansion is propelled by telehealth-enabled prescription services, the first U.S. OTC daily pill approval, and rising demand for long-acting methods. Online pharmacies already outpace every other channel, expanding at an 8.65% CAGR, while hospital pharmacies still hold the largest 40.1% revenue share. North America commands 41.17% of global revenue thanks to favorable reimbursement frameworks, whereas Asia's 5.10% CAGR underscores significant headroom as urban consumers pivot to long-acting reversible contraceptives (LARCs). Competitive intensity remains moderate; incumbents such as Bayer AG defend share through lifecycle extensions, while newer entrants differentiate on eco-friendly technologies. Throughout 2025, sustainability, digital accessibility, and safety-driven reformulations remain the clearest opportunity lanes for the hormonal contraceptive market.
Global Hormonal Contraceptives Market Trends and Insights
Advancements in Products
Lower-dose formulations aimed at minimizing side effects are redefining product expectations. The drospirenone 3 mg/estetrol 14.2 mg pill-the first combination to feature a novel estrogen in six decades-shows negligible impact on coagulation while preserving cycle control. As brands refocus on active-ingredient profiles, they deliver a differentiated safety narrative attractive to risk-averse users.
High Incidence of Unintended Pregnancies and Supportive Government Policies
Roughly 40% of global pregnancies are unintended, driving public funding for family-planning programs. In the United States, 21 million women received publicly supported contraceptive services in 2025 at a cost of USD 2.1 billion; every dollar spent saves USD 4.26 in healthcare outlays. Federal rules mandating no-cost coverage of FDA-approved methods strengthen baseline demand.
Rising Social Media Backlash on Hormone-Related Side-Effects
Nearly 1 in 5 contraceptive-related social posts discuss adverse events, amplifying discontinuation risk. Influencers with large followings can turn isolated incidents into global talking points within hours, prompting regulators to revisit safety language sooner than planned and compelling brands to invest more in real-time reputation monitoring.
Other drivers and restraints analyzed in the detailed report include:
Telehealth-Enabled Prescription FulfillmentRising OTC Approval of Oral Contraceptive PillsSupply Bottlenecks in Key APIs such as Levonorgestrel
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Oral pills retained a 42.82% share in 2025, powered by decades of clinical familiarity. OTC status for Opill widens consumer reach and could lift the hormonal contraceptive market share for pills in 2025. Implants, though accounting for a smaller revenue base, grow quickest at 7.57% CAGR on superior compliance. Twirla, a low-dose estrogen patch for users with BMI < 30 kg/m, revitalizes interest in transdermal delivery.Hormonal IUDs such as Mirena now benefit from FDA-approved use up to eight years, deepening value propositions.
Second-generation vaginal rings, lower-dose injectables, and emergency pills maintain niche relevance by addressing diverse user needs. Collectively, these modalities reinforce method mix depth that sustains the hormonal contraceptive market.
Combined estrogen-progestin products represented 60.58% of 2025 revenue. However, cardiovascular risk dialogues encourage pivot toward progestin-only choices, expected to outpace at 6.44% CAGR. The drospirenone/estetrol pill shows the combined category can still evolve with minimal coagulation effect. Meanwhile, the OTC approval of a progestin-only pill repositions that sub-segment as the safer everyday option, underpinning incremental hormonal contraceptive market size gains.
Hormonal Contraceptives Market Report is Segmented by Product (Hormonal Implants, Vaginal Rings and More), Hormone (Combined and Progestin Only), Usage Duration (SARCs and LARCs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More), End-User (Home Use, Community Health Centers and More), Age Group (15 - 24 Years, 25 - 34 Years and More) and Geography. The Market and Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America held 35.98% of 2025 revenue. The FDA's OTC pill decision and insurance mandates bolster usage. Political uncertainty around Title X funding could temper clinic reach, yet digital fulfillment offsets potential setbacks.
Asia-Pacific, posting a 6.04% CAGR, captures latent demand in urban India, Indonesia, and China. Contraceptive disparities between metropolitan and rural counties highlight infrastructure needs; targeted public programs aim to close gaps, enlarging the hormonal contraceptive market size across the region.
Europe maintains stable uptake under universal coverage, yet stricter antitrust scrutiny challenges pricing flexibility. Latin America benefits from public initiatives, but affordability issues and cultural norms restrain rapid acceleration. The Middle East and Africa display uneven penetration; South Africa and Nigeria emerge as focus markets, aided by donor-supported supply chains. Oceania contributes steady volumes but small absolute value due to the population scale.
List of Companies Covered in this Report:
Bayer Pfizer Teva Pharmaceutical Industries Johnson&Johnson AbbVie Inc. (incl. Allergan) Agile Therapeutics TherapeuticsMD Organon Perrigo Company plc (HRA Pharma) Viatris (Mylan) The Cooper Companies Gedeon Richter Plc Afaxys Inc. Cipla Lupin GlenmarkPharmaceuticals Amneal Pharmaecuticals Sun Pharmaceuticals Industries Sandoz Group Exeltis USA Shanghai Dahua Pharmaceutical Co. Ltd.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Advancements in Products
4.2.2 High Incidence of Unintended Pregnancies and Supportive Government Policies
4.2.3 Telehealth-Enabled Prescription Fulfilment
4.2.4 Rising OTC Approval of Oral Contraceptive Pills
4.2.5 Shift Toward Eco-Friendly, Biodegradable Patch Materials
4.2.6 Awareness for Family Planning and Delayed Pregnancy Trend
4.3 Market Restraints
4.3.1 Rising Social Media Backlash on Hormone-Related Side-Effects
4.3.2 Supply Bottlenecks in Key APIs such as Levonorgestrel
4.3.3 Price Caps on Essential Drugs Limiting Profit Pools
4.3.4 Availability of Alternatives
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Product
5.1.1 Oral Contraceptives
5.1.2 Transdermal Skin Patches
5.1.3 Hormonal Injectables
5.1.4 Vaginal Rings
5.1.5 Intrauterine Devices (Hormonal)
5.1.6 Hormonal Implants
5.1.7 Emergency Pills
5.1.8 Others
5.2 By Hormone
5.2.1 Combined (Estrogen + Progestin)
5.2.2 Progestin-Only
5.3 By Usage Duration
5.3.1 Short-Acting Reversible Contraceptives (SARCs)
5.3.2 Long-Acting Reversible Contraceptives (LARCs)
5.4 By Distribution Channel
5.4.1 Hospital Pharmacies
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies & E-commerce
5.4.4 NGOs and Public Health Clinics
5.5 By End User
5.5.1 Hospitals and Gynecology Clinics
5.5.2 Household / At-home Use
5.5.3 Community Health Centers
5.6 By Age Group
5.6.1 15- 24 Years
5.6.2 25 -34 Years
5.6.3 35- 44 Years
5.6.4 Above 44 Years
5.7 Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East and Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East and Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Bayer AG
6.4.2 Pfizer Inc.
6.4.3 Teva Pharmaceutical Industries Ltd.
6.4.4 Johnson & Johnson Services, Inc.
6.4.5 AbbVie Inc. (incl. Allergan)
6.4.6 Agile Therapeutics
6.4.7 TherapeuticsMD Inc.
6.4.8 Organon & Co.
6.4.9 Perrigo Company plc (HRA Pharma)
6.4.10 Viatris (Mylan)
6.4.11 CooperSurgical Inc.
6.4.12 Gedeon Richter Plc
6.4.13 Afaxys Inc.
6.4.14 Cipla Limited
6.4.15 Lupin Limited
6.4.16 Glenmark Pharmaceuticals Ltd.
6.4.17 Amneal Pharmaecuticals
6.4.18 Sun Pharmaceutical Industries Ltd.
6.4.19 Sandoz
6.4.20 Exeltis USA Inc.
6.4.21 Shanghai Dahua Pharmaceutical Co. Ltd.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security